Literature DB >> 21731977

[Antimicrobial susceptibility testing in clinically relevant non-fermenting gram-negative bacilli: recommendations from the Antimicrobial Agents Subcommittee of the Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas, Asociación Argentina de Microbiología].

Marcela Radice1, Marcelo Marín, Marta Giovanakis, Carlos Vay, Marisa Almuzara, Adriana Limansky, José M Casellas, Angela Famiglietti, Mirta Quinteros, Carlos Bantar, Marcelo Galas, Jaime Kovensky Pupko, Federico Nicola, Fernando Pasterán, Rolando Soloaga, Gabriel Gutkind.   

Abstract

This document contains the recommendations for antimicrobial susceptibility testing of the clinically relevant non-fermenting gram-negative bacilli (NFGNB), adopted after conforming those from international committees to the experience of the Antimicrobial Agents Subcommittee members and invited experts. This document includes an update on NFGNB classification and description, as well as some specific descriptions regarding natural or frequent antimicrobial resistance and a brief account of associated resistance mechanisms. These recommendations not only suggest the antimicrobial drugs to be evaluated in each case, but also provide an optimization of the disk diffusion layout and a selection of results to be reported. Finally, this document also includes a summary of the different methodological approaches that may be used for detection and confirmation of emerging b-lactamases, such as class A and B carbapenemases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21731977     DOI: 10.1590/S0325-75412011000200012

Source DB:  PubMed          Journal:  Rev Argent Microbiol        ISSN: 0325-7541            Impact factor:   1.852


  1 in total

1.  Extensively drug-resistant (XDR) Pseudomonas aeruginosa identified in Lima, Peru co-expressing a VIM-2 metallo-β-lactamase, OXA-1 β-lactamase and GES-1 extended-spectrum β-lactamase.

Authors:  Paul Ríos; Claudio Rocha; William Castro; Maria Vidal; Enrique Canal; Manuela Bernal; Nathanael D Reynolds; Drake H Tilley; Mark P Simons
Journal:  JMM Case Rep       Date:  2018-06-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.